Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease

Crystal GaoPeter MacCallum Cancer Centre, Melbourne, Australia;

Sean HarropPeter MacCallum Cancer Centre, Melbourne, Australia; ;Epworth Healthcare, Melbourne, Australia; Correspondence[email protected]

http://orcid.org/0000-0001-8867-0647

Carrie Van Der WeydenPeter MacCallum Cancer Centre, Melbourne, Australia;

Chris McCormackPeter MacCallum Cancer Centre, Melbourne, Australia; ;Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia

H. Miles PrincePeter MacCallum Cancer Centre, Melbourne, Australia; ;Epworth Healthcare, Melbourne, Australia; ;Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia

References

Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–4035.
PubMed Web of Science ®Google Scholar
Melchers RC, Willemze R, Vermaat JSP, et al. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood. 2020;135(10):769–773.
PubMed Web of Science ®Google Scholar
Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229–240.
PubMed Web of Science ®Google Scholar
Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Primary cutaneous anaplastic large cell lymphoma and evolving clinical practice: 26 years of skin lesions with locoregional progression to systemic disease

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date